Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan
29 recruiting
Showing 1–20 of 35 trials
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled60 locationsNCT07252232
Recruiting
Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
Solid Tumor
Astellas Pharma Inc681 enrolled66 locationsNCT05382559
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Endometrial Cancer
Daiichi Sankyo710 enrolled75 locationsNCT07022483
Recruiting
Phase 2Phase 3
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Solid Cancer
Daiichi Sankyo860 enrolled164 locationsNCT06161025
Recruiting
Phase 2
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
National Cancer Center, Japan136 enrolled18 locationsNCT07699939
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled366 locationsNCT05253651
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled152 locationsNCT06881784
Recruiting
Phase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Follicular LymphomaLymphoma Diffuse Large B-cellLymphoma, Non-Hodgkin's
Eli Lilly and Company460 enrolled46 locationsNCT07226843
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Recurrent Triple-Negative Breast Cancer
Yukinori Ozaki24 enrolled14 locationsNCT06976944
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Endometrial CancerRecurrent or Progressive Endometrial Cancer
Genmab660 enrolled120 locationsNCT07166094
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ovarian Cancer
Daiichi Sankyo582 enrolled208 locationsNCT06819007
Recruiting
Phase 1
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Colorectal, Cancer
EMD Serono Research & Development Institute, Inc.200 enrolled35 locationsNCT05464030
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1
A Study of LY4175408 in Participants With Advanced Cancer
Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Carcinoma, Non-Small Cell LungOvarian NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company495 enrolled23 locationsNCT06400472
Recruiting
Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled82 locationsNCT05614739
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 1Phase 2
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Advanced Solid TumorMalignant Solid Tumor
Daiichi Sankyo250 enrolled28 locationsNCT04145622